DK0764632T3 - Selektive beta3-adrenerge agonister - Google Patents

Selektive beta3-adrenerge agonister

Info

Publication number
DK0764632T3
DK0764632T3 DK96306850T DK96306850T DK0764632T3 DK 0764632 T3 DK0764632 T3 DK 0764632T3 DK 96306850 T DK96306850 T DK 96306850T DK 96306850 T DK96306850 T DK 96306850T DK 0764632 T3 DK0764632 T3 DK 0764632T3
Authority
DK
Denmark
Prior art keywords
adrenergic agonists
diabetes
type
selective
beta3
Prior art date
Application number
DK96306850T
Other languages
English (en)
Inventor
Thomas Alan Crowell
Mark Alan Winter
Christopher John Rito
John Hampton Mcdonald
Deborah Ann Evrard
Donald Paul Matthews
Anthony John Shuker
Michael Gregory Bell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0764632T3 publication Critical patent/DK0764632T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
DK96306850T 1995-09-21 1996-09-20 Selektive beta3-adrenerge agonister DK0764632T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US408395P 1995-09-21 1995-09-21

Publications (1)

Publication Number Publication Date
DK0764632T3 true DK0764632T3 (da) 2001-09-24

Family

ID=21709054

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96306850T DK0764632T3 (da) 1995-09-21 1996-09-20 Selektive beta3-adrenerge agonister

Country Status (23)

Country Link
EP (1) EP0764632B1 (da)
JP (1) JPH11513376A (da)
KR (1) KR19990045727A (da)
CN (1) CN1202106A (da)
AT (1) ATE203511T1 (da)
AU (1) AU715493B2 (da)
BR (1) BR9610481A (da)
CA (1) CA2232090A1 (da)
CZ (1) CZ82198A3 (da)
DE (1) DE69614057T2 (da)
DK (1) DK0764632T3 (da)
EA (1) EA001217B1 (da)
ES (1) ES2158996T3 (da)
GR (1) GR3036963T3 (da)
HU (1) HUP9802257A3 (da)
IL (1) IL123677A0 (da)
NO (1) NO981204L (da)
NZ (1) NZ318712A (da)
PL (1) PL325865A1 (da)
PT (1) PT764632E (da)
SI (1) SI0764632T1 (da)
TR (1) TR199800521T1 (da)
WO (1) WO1997010822A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040017A2 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EP1036064A4 (en) 1997-12-05 2002-11-27 Lilly Co Eli SELECTIVE BETA 3-ADRENERGIC ANTAGONISTS
MY121054A (en) * 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
AUPP796798A0 (en) * 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2001035947A2 (en) * 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
AU1580001A (en) * 1999-11-15 2001-05-30 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
FR2809725B1 (fr) * 2000-06-06 2004-05-07 Sanofi Synthelabo Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
AU2003248352A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498999A (en) * 1966-04-20 1970-03-03 Bristol Myers Co 1-phenoxy and substituted phenoxy-3-(5-tetrazolyl) propanes
GB1433920A (en) * 1973-10-01 1976-04-28 Ici Ltd Alkanolamine derivatives
US4080471A (en) * 1976-06-25 1978-03-21 Aktiebolaget Hassle Use of substituted isopropylaminopropanols for inducing inotropic effects of the human heart
FR2640969B1 (da) * 1988-12-23 1991-11-22 Midy Spa
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
EP0627407A1 (fr) * 1993-05-28 1994-12-07 MIDY S.p.A. Acide (7S)-7-[(2R)-2(3-chlorophényl)-2-hydroxyéthylamino]-5,6,7,8-tétrahydronaphtalèn-2-yloxy acétique, ses sels pharmaceutiquement acceptables, à action agoniste bêta-3 adrénergique et compositions pharmaceutiques le contenant
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists

Also Published As

Publication number Publication date
PL325865A1 (en) 1998-08-17
CZ82198A3 (cs) 1998-07-15
DE69614057T2 (de) 2002-03-14
EA001217B1 (ru) 2000-12-25
AU7077096A (en) 1997-04-09
EA199800317A1 (ru) 1998-10-29
ATE203511T1 (de) 2001-08-15
TR199800521T1 (xx) 1998-06-22
HUP9802257A2 (hu) 1999-02-01
HUP9802257A3 (en) 1999-04-28
BR9610481A (pt) 1999-05-11
ES2158996T3 (es) 2001-09-16
NO981204L (no) 1998-04-17
JPH11513376A (ja) 1999-11-16
EP0764632A3 (en) 1997-12-10
NZ318712A (en) 1999-08-30
GR3036963T3 (en) 2002-01-31
PT764632E (pt) 2001-12-28
NO981204D0 (no) 1998-03-17
DE69614057D1 (de) 2001-08-30
EP0764632B1 (en) 2001-07-25
CA2232090A1 (en) 1997-03-27
KR19990045727A (ko) 1999-06-25
SI0764632T1 (en) 2001-12-31
EP0764632A2 (en) 1997-03-26
MX9802097A (es) 1998-08-30
CN1202106A (zh) 1998-12-16
IL123677A0 (en) 1998-10-30
AU715493B2 (en) 2000-02-03
WO1997010822A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
MX9802130A (es) Agonistas adrenergicos beta3 selectivos.
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
ATE203511T1 (de) Selektive beta3-adrenergische agonisten
DE69939705D1 (de) Behandlung der pompeschen krankheit
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
FI953467A0 (fi) Aminohappojohdannaisia, näitä yhdisteitä sisältävät lääkeaineet ja menetelmä niiden valmistamiseksi
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
NO972128D0 (no) 2,2-dikloralkankarboksylsyrer, fremgangsmåte for fremstilling av disse, legemiddel inneholdende disse og anvendelse derav for behandling av insulinresistens
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
KR880007070A (ko) 백내장 치료용 약학 조성물
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
ES2109512T3 (es) Macrolactama (ciclamenol) antiinflamatoria.
CA2236269A1 (en) Selective .beta.3 adrenergic agonists
RU93008438A (ru) Способ лечения острых респираторных заболеваний
IT8919215A0 (it) Dispositivo per la cura chirurgica dell'ametropia.
EA199700053A1 (ru) Новые применения 2-[n-(1,2-бензизотиазолил-3(2h)он-1,1-диоксид]этил 5-этоксикарбонил-2,4,6-триметил-1,4-дигидропиридин-3-карбоксилата